NASDAQ : REGN
Regeneron Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 927.89 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 92.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 93.11B |
| Enterprise Value | 76.96B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Nov 20, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 98.53M |
| Shares Outstanding | 100.35M |
| Shares Change (YoY) | -3.11% |
| Shares Change (QoQ) | -0.38% |
| Owned by Insiders (%) | 3.81% |
| Owned by Institutions (%) | 93.10% |
| Float | 96.34M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 20.54 |
| Forward PE | 11.83 |
| PS Ratio | 5.51 |
| Forward PS | 4.48 |
| PB Ratio | 2.78 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | 24.33 |
| P/OCF Ratio | 19.21 |
| PEG Ratio | 1.00 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 15.98 |
| EV / Sales | 4.55 |
| EV / EBITDA | 13.63 |
| EV / EBIT | 14.99 |
| EV / FCF | 20.11 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.35 |
| Quick Ratio | 2.72 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.48 |
| Debt / FCF | 0.71 |
| Interest Coverage | 109.93 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 14.95% |
| Return on Assets (ROA) | 7.59% |
| Return on Invested Capital (ROIC) | 16.31% |
| Return on Capital Employed (ROCE) | 13.44% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $313,980 |
| Employee Count | 15,343 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.93 |
Taxes
| Measure | Value |
|---|
| Income Tax | 869.40M |
| Effective Tax Rate | 15.29% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +42.12% |
| 50-Day Moving Average | 793.30 |
| 200-Day Moving Average | 737.54 |
| Relative Strength Index (RSI) | 79.11 |
| Average Volume (20 Days) | 745,167 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.13M |
| Short Previous Month | 2.15M |
| Short % of Shares Out | 2.13% |
| Short % of Float | 2.22% |
| Short Ratio (days to cover) | 2.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 16.90B |
| Gross Profit | 7.90B |
| Operating Income | 5.13B |
| Pretax Income | 5.69B |
| Net Income | 4.82B |
| EBITDA | 5.65B |
| EBIT | 5.13B |
| Earnings Per Share (EPS) | $45.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.30B |
| Total Debt | 2.71B |
| Net Cash | 16.15B |
| Net Cash Per Share | $160.96 |
| Equity (Book Value) | 33.50B |
| Book Value Per Share | 333.93 |
| Working Capital | 14.59B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 4.85B |
| Capital Expenditures | -1.02B |
| Depreciation & Amortization | 512.90M |
| Net Borrowing | n/a |
| Free Cash Flow | 3.83B |
| FCF Per Share | $38.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | 46.73% |
| Operating Margin | 30.38% |
| Pretax Margin | 33.66% |
| Profit Margin | 28.51% |
| EBITDA Margin | 33.42% |
| EBIT Margin | 30.38% |
| FCF Margin | 22.65% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $3.76 |
| Dividend Yield | 0.41% |
| Dividend Growth (YoY) | 6.82% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.32% |
| FCF Payout Ratio | 9.86% |
| Buyback Yield | 3.11% |
| Shareholder Yield | 3.52% |
| Earnings Yield | 4.87% |
| FCF Yield | 4.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $964.04 |
| Price Target Difference | 3.90% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 14.36% |
| EPS Growth Forecast (3Y) | 20.03% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.44 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |